Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations

Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations.MOUNTAIN VIEW, Calif. and DOWNINGTOWN, Pa. and TAMPA, Fla., Nov. 4, 2013 /PRNewswire

Edison Pharmaceuticals, the Friedreich's Ataxia Research Alliance (FARA) and the University of South Florida (USF) today announced the initiation of a phase 2 study entitled, "Phase 2A Clinical Trial of EPI-743 on Visual Function in Friedreich's Ataxia Patients with Point Mutations."

Related content: EPI-743 in Friedreich's Ataxia Point Mutations, Thursday, October 17, 2013